Breaking News Instant updates and real-time market news.

BRKS

Brooks Automation

$26.56

-0.37 (-1.37%)

, IMMU

Immunomedics

$16.67

-0.57 (-3.31%)

09:55
01/10/19
01/10
09:55
01/10/19
09:55

JPMorgan to hold a conference

37th Annual Healthcare Conference will be held in San Francisco on January 7-10 with webcasted company presentations to begin on January 10 at 10:30 am; not all company presentations may be webcasted. Webcast Link

BRKS

Brooks Automation

$26.56

-0.37 (-1.37%)

IMMU

Immunomedics

$16.67

-0.57 (-3.31%)

AXON

Axovant Sciences

$1.11

-0.025 (-2.20%)

AVNS

Avanos

$44.42

-0.18 (-0.40%)

CLSD

Clearside Biomedical

$1.17

(0.00%)

ZIOP

Ziopharm

$2.23

-0.03 (-1.33%)

OMI

Owens & Minor

$7.04

-0.01 (-0.14%)

INFI

Infinity Pharmaceuticals

$1.30

(0.00%)

AUPH

Aurinia Pharmaceuticals

$7.08

-0.01 (-0.14%)

VIVO

Meridian Bioscience

$15.90

(0.00%)

INSY

Insys Therapeutics

$4.52

0.04 (0.89%)

MGNX

MacroGenics

$13.50

-0.31 (-2.24%)

RTRX

Retrophin

$23.13

(0.00%)

VSTM

Verastem

$3.97

-0.11 (-2.70%)

VCYT

Veracyte

$15.30

0.09 (0.59%)

  • 10

    Jan

  • 15

    Jan

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 24

    Jan

  • 25

    Feb

  • 30

    Jun

BRKS Brooks Automation
$26.56

-0.37 (-1.37%)

11/20/18
FBCO
11/20/18
NO CHANGE
Target $26
FBCO
Neutral
Brooks Automation price target lowered to $26 from $32 at Credit Suisse
Credit Suisse analyst John Pitzer lowered his price target for Brooks Automation to $26 from $32 after the company reported Q3 revenues in line, with EPS slightly above estimates, and guided Q4 below due to the divestiture of the Semiconductor Cryogenics business and the acquisition of the Genewiz business. The analyst reiterates a Neutral rating on the shares.
09/04/18
RILY
09/04/18
NO CHANGE
Target $50
RILY
Buy
Brooks Automation price target raised to $50 from $40 at B. Riley FBR
B. Riley FBR analyst Craig Ellis raised his price target for Brooks Automation to $50 citing the company's intensifying push into life sciences. The analyst reiterates a Buy rating on the shares.
08/29/18
JANY
08/29/18
NO CHANGE
Target $56
JANY
Buy
Brooks Automation price target raised to $56 from $40 at Janney Montgomery Scott
Janney Montgomery Scott analyst Paul Knight noted that Brooks Automation announced the sale of its Cryo Vacuum semiconductor business, which he identifies as its lowest growth semi-business, for $675M. The sale means Life Science will grow to about 40% from 28% as a percentage of total revenue and the company is targeting even more Life Science M&A, said Knight, who raised his fair value estimate on Brooks Automation shares to $56 from $40 following the deal. He maintains a Buy rating on the stock.
12/17/18
SBSH
12/17/18
NO CHANGE
SBSH
Buy
Citi adds 'positive catalyst watch' on Brooks Automation
Citi analyst Amanda Scarnati adds a "positive catalyst watch" on Brooks Automation after meeting with the company's management. The analyst says Brooks sounded the most positive of the group on her firm's bus tour, largely due to its "solid exposure to the life sciences market," Scarnati tells investors in a research note. The analyst expects Brooks Automation's relative share outperformance to continue in the first half of 2019 as the life sciences business continues to grow as a percentage of sales and the sale of the "low growth" semi cryo business closes. Scarnati has a Buy rating on the shares.
IMMU Immunomedics
$16.67

-0.57 (-3.31%)

01/07/19
RILY
01/07/19
INITIATION
Target $55
RILY
Buy
Immunomedics resumed with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty resumed coverage on Immunomedics with a Buy and $55 price target.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Outperform
Immunomedics appears confident in sacituzumab approval odds, says Wells Fargo
Wells Fargo analyst Jim Birchenough attributes this morning's pressure on Immunomedics shares to concerns regarding potential observations at the companies manufacturing facility and implications for approval of sacituzumab govitecan for triple negative breast cancer by its PDUFA date of January 18. However, after speaking to management, he said they indicated that the FDA observations occurred as part of a pre- approval inspection in early August, are "old news" and that a remediation has long been put in place. He said that the company "appears confident" in the prospects for approval of sacituzumab govitecan and maintains an Outperform rating on the stock, which remains down 23% in late morning trading.
12/20/18
PIPR
12/20/18
NO CHANGE
Target $33
PIPR
Overweight
Immunomedics' 'overdone' pullback an opportunity to buy, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro attributes the 20% decline in Immunomedics shares to the circulation of a report that highlights the issuance of a Form 483 following a pre-approval manufacturing inspection this past August. Immunomedics management emphasized that they continue to interact with the FDA on almost a daily basis and feel they are "in a very good place," said Catanzaro, who views the pullback as overdone and would be a buyer on weakness. He keeps an Overweight rating on Immunomedics, citing his confidence that sacituzumab will be approved by its January PDUFA date.
12/20/18
MSCO
12/20/18
NO CHANGE
Target $38
MSCO
Overweight
Immunomedics sees key manufacturing issues as remediated, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison spoke with Immunomedics management following a short report being published and noted that the company indicated that issues the FDA communicated in a Form-483 were discovered as part of a ramp to GMP quality in late 2017 and early 2018. Management also said they'd begun remediation of the issues "well prior" to the 483 receipt and have worked to remediate all the key issues. He appreciates the concern in the market, given that investors have been worried about manufacturing issues potentially impacting the approval of IMMU-132, but Harrison still believes there is a higher probability of approval than not on the PDUFA. He keeps an Overweight rating on Immunomedics shares with a $38 price target.
AXON Axovant Sciences
$1.11

-0.025 (-2.20%)

01/12/18
01/12/18
DOWNGRADE

Market Perform
Axovant Sciences downgraded after intepirdine failure at Cowen
As previously reported, Cowen analyst Ritu Baral downgraded Axovant Sciences to Market Perform from Outperform following the failure of the HEADWAY and Gait studies for intepirdine. Additionally, nelotanserin data have deteriorated since a mid-2017 interim look, added Baral, who now sees Axovant "as a SPAC," or special purpose acquisition company, with "limited clarity."
06/11/18
JEFF
06/11/18
NO CHANGE
Target $5
JEFF
Hold
Axovant Sciences price target raised to $5 from $3 at Jefferies
Following Axovant Sciences' in-licensing of AXO-Lenti-PD, Jefferies analyst Michael Yee said he thinks the asset is "interesting" and looks forward to new data potentially 2019, but he also appreciates the stock has already had a big move and it may take some time to create new value. Yee, who thinks the company has cash to do deals and may add yet another product this year, raised his price target on Axovant shares to $5 from $3 and keeps a Hold rating on the stock.
12/17/18
JEFF
12/17/18
UPGRADE
Target $3
JEFF
Buy
Axovant Sciences upgraded to Buy from Hold at Jefferies
Jefferies analyst Michael Yee upgraded Axovant Sciences to Buy and raised his price target for the shares to $3.00. Data readouts over the next year could drive a "meaningful percentage" return for small cap investors and take Axovant shares to $3 from $1 in 2019, Yee tells investors in a research note. The analyst views the current valuation as "cheap" and recommends buying the stock with the company's three gene therapy programs having catalysts in 2019. He believes Axovant's risk/reward is skewed to the upside.
01/12/18
COWN
01/12/18
DOWNGRADE
COWN
Market Perform
Axovant Sciences downgraded to Market Perform from Outperform at Cowen
AVNS Avanos
$44.42

-0.18 (-0.40%)

08/21/18
08/21/18
UPGRADE
Target $75

Outperform
Avanos upgraded to Outperform following management meetings at Raymond James
As previously reported, Raymond James upgraded Avanos to Outperform from Market Perform and established a $75 price target. Following recent management meetings, analyst Lawrence Keusch said he has increased confidence that organic growth and margin expansion can outperform consensus expectations as management executes on its long-range plan. Keusch also has increased confidence in the M&A strategy and thinks a deal could happen in 2H 2019. The analyst raised his 2019 and 2020 estimates above the Street and said Avanos shares are trading at a discount to ppers.
01/04/19
LEHM
01/04/19
DOWNGRADE
Target $36
LEHM
Underweight
Avanos downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Kristen Stewart downgraded Avanos Medical (AVNS) to Underweight and lowered her price target for the shares to $36 from $59. Following a review of the pain medicine landscape the analyst has increased concerns regarding the outlook for the company's ON-Q Pump. Drug shortages are likely to persist into mid-year, Stewart tells investors in a research note. Further, she has longer-term concerns around the potential FDA approval and launch of Heron Therapeutics' (HRTX) HTX-011.
01/02/19
SPHN
01/02/19
NO CHANGE
SPHN
CBS, Global Payments, Union Pacific among Stephens' best ideas for 2019
Stephens released its Best Ideas list for 2019, noting that over the last 13 years its Best Ideas list has outperformed the Russell 2000 by an average of 300 bps. Of note, six of the firm's 30 analysts listed "cash" as their best idea for this year. Among the rest, the picks included: Landstar System (LSTR), Enova (ENVA), RealPage (RP), FMC Corporation (FMC), Avanos (AVNS), Knight-Swift (KNX), CBS (CBS), Vulcan Materials (VMC), Encompass Health (EHC), Watsco (WSO), Global Payments (GPN), O'Reilly Automotive (ORLY), NeoGenomics (NEO), Continental Resources (CLR), Union Pacific (UNP), Ametek (AME), Wintrust Financial (WTFC), Helmerich & Payne (HP), Penske Automotive (PAG), Signature Bank (SBNY), Noble Energy (NBL), Origin Bancorp (OBNK), GrubHub (GRUB) and CenterState Bank (CSFL).
10/15/18
LEHM
10/15/18
INITIATION
LEHM
Equal Weight
Avanos initiated with an Equal Weight at Barclays
Barclays analyst Kristen Stewart initiated Avanos with an Equal Weight rating and $69 price target.
CLSD Clearside Biomedical
$1.17

(0.00%)

11/05/18
STFL
11/05/18
DOWNGRADE
Target $4
STFL
Hold
Clearside Biomedical downgraded to Hold from Buy at Stifel
Stifel analyst Annabel Samimy earlier downgraded Clearside Biomedical to Hold from Buy following the failure of the SAPPHIRE trial in RVO and subsequent discontinuation of the program. Clearside's value now depends primarily on the success of Xipere for the treatment of macular edema associated with non-infectious uveitis, said Samimy, who lowered her price target on the stock to $4 from $20. The SAPPHIRE failure also has implications for the future clinical design for DME, since "designing it as a superiority trial appears off the table now," Samimy believes.
11/05/18
COWN
11/05/18
DOWNGRADE
COWN
Market Perform
Clearside Biomedical downgraded earlier to Market Perform at Cowen
11/05/18
JPMS
11/05/18
DOWNGRADE
Target $8
JPMS
Underweight
JPMorgan double downgrades Clearside to Underweight on study failure
JPMorgan analyst Anupam Rama double downgraded Clearside Biomedical to Underweight from Overweight and lowered his price target for the shares to $8 from $16. The stock in early trading is down 56%, or $3.12, to $2.44. The analyst also removed Clearside from his firm's Analyst Focus List. The company this morning announced that the Phase 3 Sapphire results for Xipere plus Eylea in retinal vein occlusion did not meet the primary endpoint of third-line gainers versus Eylea alone, Rama tells investors in a research note. The results are "clearly disappointing," says Rama. The analyst sees no material value creation catalysts on the horizon and believes the overall negative sentiment on shares is unlikely to change until the company is closer to approval/commercialization.
11/06/18
NEED
11/06/18
NO CHANGE
Target $4
NEED
Buy
Clearside Biomedical price target lowered to $4 from $22 at Needham
Needham analyst Serge Belanger lowered his price target on Clearside Biomedical to $4 after its announcement yesterday that the Sapphire Phase 3 study evaluating Xipere in RVO patients did not meet its primary endpoint. The analyst also keeps his Buy rating, stating that while Clearside Biomedical is discontinuing the clinical development of its RVO program, it will remain focused on the Xipere opportunity in uveitis. Belanger adds that the valuation on the shares is now below cash levels and fails to capture the uveitis opportunity with potential peak sales of as high as $150M.
ZIOP Ziopharm
$2.23

-0.03 (-1.33%)

11/15/18
11/15/18
UPGRADE
Target $5

Outperform
Ziopharm upgraded to Outperform at Raymond James
As previously reported, Raymond James analyst Reni Benjamin upgraded Ziopharm to Outperform from Market Perform, with a $5 price target. The analyst notes that the company provided an update on its cell and gene therapy programs in a recent conference call, saying it has severed its relationship with Intrexon, eliminating $157M million in preferred stock and significantly simplifying its corporate structure. Additionally, Ziopharm said that in conjunction with Steven Rosenberg and the NCI, it plans to utilize the Sleeping Beauty neoantigen platform to generate patient specific TCRs, with the filing of an IND expected by year end 2018/early 2019, he pointed out, adding that a cash infusion of $50M from long-term investors should extend the company's cash runway to Q2 of 2020.
11/15/18
RAJA
11/15/18
UPGRADE
RAJA
Outperform
Ziopharm upgraded to Outperform from Market Perform at Raymond James
06/19/18
HCWC
06/19/18
NO CHANGE
Target $5.5
HCWC
Buy
Ziopharm selloff brings buying opportunity, says H.C. Wainwright
The clinical hold placed on Ziopharm's third generation point-of-care CAR-T program is unlikely to bring a significant delay, H.C. Wainwright analyst Swayampakula Ramakanth tells investors in a research note. The analyst views yesterday's 18% share pullback as a buying opportunity and reiterates a Buy rating on Ziopharm with a $5.50 price target. He notes that neither of the Ziopharm's clinical programs on Ad-RTS-hIL-12 or second generation CD19 and CD33 CAR-Ts has been affected by the clinical hold. The clinical hold is more akin to the FDA putting a "pause" on the investigational new drug application review process while the company prepares the response, Ramakanth argues.
06/18/18
JPMS
06/18/18
DOWNGRADE
JPMS
Underweight
Ziopharm downgraded to Underweight from Neutral at JPMorgan
OMI Owens & Minor
$7.04

-0.01 (-0.14%)

02/27/18
BOFA
02/27/18
INITIATION
Target $19
BOFA
Buy
Owens & Minor reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Michael Cherny reinstated coverage on Owens & Minor with a Buy and $19 price target.
03/08/18
LEHM
03/08/18
INITIATION
Target $16
LEHM
Underweight
Owens & Minor initiated with an Underweight at Barclays
Barclays analyst Steve Valiquette started Owens & Minor with an Underweight rating and $16 price target. The analyst initiated 14 companies in Health Care Services with a Neutral industry view.
10/31/18
BOFA
10/31/18
DOWNGRADE
BOFA
Neutral
Owens & Minor downgraded to Neutral from Buy at BofA/Merrill
02/14/18
JEFF
02/14/18
NO CHANGE
JEFF
Amazon focusing on bolstering medical device distribution, says Jefferies
Yesterday's Wall Street Journal report and a recent scan of job postings still point to Amazon.com's (AMZN) focus on bolstering its medical device/supplies distribution capabilities, specifically targeting hospitals, Jefferies analyst Brian Tanquilut. These postings support a negative thesis for Cardinal Health (CAH), Owens & Minor (OMI) and Premier's (PINC) medical supplies businesses, the analyst adds. Further, he sees the news as an incremental positive for AmerisourceBergen (ABC), McKesson (MCK), CVS Health (CVS) and Walgreens Boots Alliance (WBA) since it further supports the view that Amazon isn't looking to enter the prescription business near-term.
INFI Infinity Pharmaceuticals
$1.30

(0.00%)

01/04/19
01/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aveo Pharmaceuticals (AVEO) initiated with an Outperform at Baird. 2. Catalyst Biosciences (CBIO) initiated with Outperform at Oppenheimer. 3. Infinity Pharmaceuticals (INFI) initiated with a Buy at B. Riley FBR. 4. Rockwell Automation (ROK) resumed with a Hold at Deutsche Bank. 5. Dell Technologies (DELL) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/04/19
RILY
01/04/19
INITIATION
Target $3
RILY
Buy
Infinity Pharmaceuticals initiated with a Buy at B. Riley FBR
B. Riley FBR George Zavoico started Infinity Pharmaceuticals with a Buy rating and $3 price target. The company could "hold the key" to improving checkpoint inhibitors in cancer, Zavoico tells investors in a research note.
11/12/18
11/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yelp (YELP) downgraded to Hold om Buy at SunTrust with analyst Matthew Thornton citing a surprising and disappointing set of Q3 results following a "stellar" first half of 2018, highlighted by the return of sales execution issues, yielding an unexpected slowdown in gross account adds and continued churn. 2. Cheesecake Factory (CAKE) downgraded to Underweight from Equal Weight at Barclays with analyst Jeffrey Bernstein saying he sees headwinds persisting following the company's "disappointing" Q3 results and views the valuation as full at current share levels. 3. Infinity Pharmaceuticals (INFI) downgraded to Underweight from Neutral at JPMorgan and to Market Perform at Wells Fargo. 4. Skyworks (SWKS) downgraded to Neutral from Buy at Citi with analyst Atif Malik saying the company is being impacted by broad smartphone weakness, disappointing unit sales of Apple's (AAPL) iPhone XR, and a high Apple concentration, which represented 39% of sales in fiscal 2019. 5. AB InBev (BUD) downgraded to Hold from Buy at Argus with analyst David Coleman citing the company's dividend cut, which he believes reduces the attraction of the stock to income investors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/12/18
JPMS
11/12/18
DOWNGRADE
JPMS
Underweight
JPMorgan downgrades Infinity to Underweight, says data needs to mature
JPMorgan analyst Anupam Rama downgraded Infinity Pharmaceuticals to Underweight from Neutral without a price target. The data for IPI-549 needs to continue to mature, Rama tells investors in a research note. After the company presented initial data from the IPI-549 plus nivolumab combination portion of the MARIO-1 study this weekend, the analyst continues to believe Infinity is a "show me" story. He thinks the shares will be a relative underperformer of his coverage universe in the first half of 2019.
AUPH Aurinia Pharmaceuticals
$7.08

-0.01 (-0.14%)

03/16/18
CANT
03/16/18
NO CHANGE
Target $16
CANT
Overweight
Aurinia price target raised to $16 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $16 citing a reduction of the company's estimated tax rate to 21% from 35% following its Q4 results. Aurinia remains on track to enroll its Phase 3 Aurora study in Q4 and to initiate studies to advance its pipeline indications for voclosporin in Q2, Piros tells investors in a research note. He reiterates an Overweight rating on the shares.
08/13/18
HCWC
08/13/18
NO CHANGE
Target $15
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $15 after the company announced its pivotal Phase 3 study of voclosporin in lupus nephritis patients is running ahead of schedule. The analyst view the progress as a reflection of the high level of interest and motivation in the trial, by both patients and investigators. He keeps a Buy rating on Aurinia shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $9
RBCM
Outperform
Aurinia Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Douglas Miehm initiated Aurinia Pharmaceuticals with an Outperform rating and a price target of $9. The analyst says the stock represents an "attractive opportunity with upside" based on the Phase 3 study of its lupus nephritis drug voclosporin, which "has potential to become the first FDA-approved treatment for the disease".
VIVO Meridian Bioscience
$15.90

(0.00%)

05/31/18
BMOC
05/31/18
NO CHANGE
Target $275
BMOC
Outperform
WellCare price target raised to $275 from $250 at BMO Capital
BMO Capital analyst Matt Borsch raised his price target for WellCare (WCG) to $275 from $250, telling investors in a research note that the implied valuation of the proposed $2.5B Meridian (VIVO) deal "looks reasonable" on a price per member basis. Specifically, he notes that the deal implies WellCare is paying about $2,000 per Medicaid managed care life and about $5,600 per Medicare Advantage life. Borsch, who has an Outperform rating on WellCare, views the company as the best-positioned growth story in Managed Care given a "modest" size, its product/market position at the intersection of Medicaid and Medicare and "significant" room for margin expansion.
INSY Insys Therapeutics
$4.52

0.04 (0.89%)

03/09/18
PIPR
03/09/18
DOWNGRADE
Target $4
PIPR
Underweight
Insys Therapeutics downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Insys Therapeutics to Underweight and cut his price target for the shares to $4 from $5. The analyst sees "no basis in reality" for the company's guidance of relatively stable total sales in 2018 versus 2017 given the nature of the opioid crisis. Further, the weak rollout of Syndros "also does not inspire confidence" in the 2018 guidance, Amsellem tells investors in a research note.
08/10/18
PIPR
08/10/18
NO CHANGE
Target $4
PIPR
Underweight
Insys DOJ settlement does not remove downside risk, says Piper Jaffray
Piper Jaffray analyst David Amsellem says the settlement with the Department of Justice does not mean there isn't downside risk in shares of Insys Therapeutics. For a $600M market capitalization, investors are getting a sublingual form of buprenorphine that was "roundly rejected" by an FDA panel in May, a cannabidiol product that has yet to demonstrate proof-of-concept in a well-controlled trial, a product in Syndros that has minimal sales after approximately one year of active promotion, and a declining asset in Subsys that has limited profitability, Amsellem tells investors in a research note following Insys' Q2 results. The analyst does not believe the shares are "adequately risk-adjusted." He reiterates an Underweight rating on Insys with a $4 price target.
12/19/18
JANY
12/19/18
INITIATION
Target $11
JANY
Buy
Insys Therapeutics assumed with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong assumed coverage of Insys Therapeutics with a Buy rating and fair value estimate of $11, down from the firm's prior $16 estimate. Zhong said Insys is shifting focus from commercializing opioid products to developing cannabinoids and proprietary spray technology, adding that he views the heated discussion during a two-day FDA AdCom on naloxone earlier this week as a "clear sign" for an increased commercial opportunity for Insys. Zhong also believes the data from the cannabidiol programs, if positive, could unlock significant upside potential.
MGNX MacroGenics
$13.50

-0.31 (-2.24%)

12/04/18
RHCO
12/04/18
DOWNGRADE
Target $75
RHCO
Hold
Tesaro downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Tesaro (TSRO) to Hold from Buy and raised his price target to $75 from $65 after its announcement of being acquired by Glaxo SmithKline (GSK). The analyst believes that the $75 per share offer price is "fair" and expects the deal, which he views as potentially positive for peers and for the biotech tape, to be completed in Q1 of 2019. Lawson anticipates that other companies with DNA damage response targeting drugs such as Sierra Oncology (SRRA), as well as immunoefficiency pipeline peers including MacroGenics (MGNX), Array Biopharma (ARRY), and Deciphera Pharmaceuticals (DCPH) could benefit from the announcement.
09/10/18
BTIG
09/10/18
INITIATION
Target $30
BTIG
Buy
MacroGenics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed MacroGenics with a Buy rating and a price target if $30, saying he is positive on its DART and TRIDENT multi-functional antibodies programs and its Fc Optimization technology that "allows antibodies to interact more strongly with immune effector cells that resolve antibody-antigen complexes". The analyst contends that while the company's monoclonal antibodies, or mAb, development space is "crowded", MacroGenics offers "nearly two decades of tough won experience" and over two years of cash runway to give its "deep pipeline" multiple opportunities to "turn heads".
12/10/18
RAJA
12/10/18
DOWNGRADE
RAJA
Underperform
MacroGenics downgraded to Underperform from Outperform at Raymond James
12/10/18
MSCO
12/10/18
NO CHANGE
MSCO
Equal Weight
MacroGenics hold doesn't impact other B7-H3 therapies, says Morgan Stanley
After MacroGenics announced the FDA has place a partial clinical hold on MGD009, Morgan Stanley analyst David Lebowitz noted that the hold is said to not impact other B7-H3 targeted therapies, including enoblituzumab and MGC018. Given MacroGenic's prior experience with flotetuzumab, he expects to see weakness in the shares on the open this morning, but Lebowitz points out that modifications for flotetuzumab allowed for better management of cytokine related AEs and that it continues to be studied. He keeps an Equal Weight rating on MacroGenics with a $21 price target. In pre-market trading, the stock is down $2.71, or 16.5%, to $13.70.
RTRX Retrophin
$23.13

(0.00%)

04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
11/19/18
NOMU
11/19/18
INITIATION
Target $57
NOMU
Buy
Retrophin initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Christopher Marai started Retrophin with a Buy rating and $57 price target. The company's pipeline assets address high unmet needs and defined markets, and each could potentially double the company's revenue, Marai tells investors in a research note. He sees "de-risking" events beginning in 2019.
10/30/18
JEFF
10/30/18
INITIATION
Target $44
JEFF
Buy
Retrophin initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Retrophin with a Buy rating and $44 price target. The company has three Phase III programs and a "robust" commercial portfolio, Raycroft tells investors in a research note. Further, he believes the management team has demonstrated to be reliable with examples of execution.
08/17/18
ADAM
08/17/18
INITIATION
Target $36
ADAM
Buy
Retrophin initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Retrophin with a Buy rating citing what she views as an attractive valuation given the upside potential provided by the clinical stage pipeline. She sees limited downside risk but upside catalysts with POC data for CNSA-001 in early 2019 and Phase 3 FORT data in PKAN in the second half 2019. Gilson has a $36 price target on Retrophin shares.
VSTM Verastem
$3.97

-0.11 (-2.70%)

09/25/18
HCWC
09/25/18
NO CHANGE
Target $15
HCWC
Buy
Verastem price target raised to $15 from $10 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Verastem to $15 after the FDA approved the company's lead product, Copiktra , for the treatment of third-line chronic lympocytic leukemia, small lympocytic leukemia, and follicular lymphoma. Not unexpectedly, the FDA has included a boxed warning highlighting the increased risk of serious infections, diarrhea, and colitis with Copiktra, the analyst adds. He expects Copiktra to generate revenues of $178M for these three indications by 2025 and keeps a Buy rating on Verastem.
07/09/18
OPCO
07/09/18
NO CHANGE
Target $16
OPCO
Outperform
Verastem price target raised to $16 from $11 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Verastem to $16 from $11 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
07/13/18
BTIG
07/13/18
INITIATION
Target $17
BTIG
Buy
Verastem initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Verastem with a Buy rating and a price target of $17. The analyst cites the potential of the company's pipeline - namely the "late-stage, first-in-class molecule Duvelisib that selectively targets the delta and gamma phosphoinositide 3-kinase isoforms, central signaling pathways in cancer cell proliferation and survival". Hazlett adds that its " successful Phase 3 DUO trial in relapsed/refractory chronic lymphocytic leukemia, combined with solid data from the Phase 2 DYNAMO study in refractory follicular lymphoma, have led to Duvelisib receiving a Priority Review from FDA" with an upcoming Oct 5th PDUFA, as well as a licensing deal. The analyst models potential U.S. peak revenue over $500M and international revenue over $350M in Duvelisib's initial indications.
08/09/18
RAJA
08/09/18
NO CHANGE
RAJA
Verastem price target raised to $12 from $7 at Raymond James
VCYT Veracyte
$15.30

0.09 (0.59%)

10/31/18
JANY
10/31/18
UPGRADE
JANY
Buy
Veracyte upgraded to Buy from Neutral at Janney Montgomery Scott
07/24/18
PIPR
07/24/18
NO CHANGE
Target $11
PIPR
Neutral
Veracyte price target raised to $11 from $7 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Veracyte to $11 following the company's Q2 sales beat and increased 2018 guidance. Veracyte is entering a "new multi-faceted growth cycle" and deserves a premium multiple, Quirk tells investors in a post-earnings research note. The analyst keeps a Neutral rating on the shares but has a "positive bias." He views the new guidance as "not only achievable but potentially beatable."
01/04/19
BTIG
01/04/19
NO CHANGE
Target $17
BTIG
Buy
Veracyte price target raised to $17 from $15 at BTIG
BTIG analyst Sung Ji Nam raised his price target on Veracyte (VCYT) to $17 and kept the Buy rating on the shares after its announced long term partnership with Johnson & Johnson (JNJ) yesterday. The analyst says the collaboration aims to accelerate the development of the first nasal swab test for early lung cancer detection and involve the two companies sharing existing data and samples from clinical studies. Sung Ji Nam states that the deal should lead to acceleration of next -gen Percepta launch, adding that the nasal swab test development could quadruple the company's total addressable market value in the U.S. alone.

TODAY'S FREE FLY STORIES

GWPH

GW Pharmaceuticals

$137.24

2.59 (1.92%)

17:03
01/18/19
01/18
17:03
01/18/19
17:03
Syndicate
Breaking Syndicate news story on GW Pharmaceuticals »

GW Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCSC

Fibrocell Science

$2.03

0.03 (1.50%)

16:55
01/18/19
01/18
16:55
01/18/19
16:55
Syndicate
Breaking Syndicate news story on Fibrocell Science »

Fibrocell Science files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

, ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Conference/Events
EnLink Midstream Partners to hold a special shareholder meeting »

Special Shareholder…

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

FDX

FedEx

$176.97

3.72 (2.15%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Hot Stocks
FedEx establishes voluntary buyout program for U.S. workers »

FedEx said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

  • 03

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

, ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

16:48
01/18/19
01/18
16:48
01/18/19
16:48
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change  »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

16:30
01/18/19
01/18
16:30
01/18/19
16:30
Options
Preliminary option volume of 26.9M today »

Preliminary option volume…

NBRV

Nabriva Therapeutics

$1.97

-0.01 (-0.51%)

16:27
01/18/19
01/18
16:27
01/18/19
16:27
Conference/Events
Nabriva Therapeutics to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Apr

VLRS

Volaris

$7.50

0.04 (0.54%)

16:21
01/18/19
01/18
16:21
01/18/19
16:21
Conference/Events
International Aviation Club to host monthly luncheon meeting »

Enrique Beltranena, CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
01/18/19
01/18
16:20
01/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for January 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
01/18/19
01/18
16:17
01/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
01/18/19
01/18
16:16
01/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$14.48

-0.57 (-3.79%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
Conference/Events
Forty Seven to hold KOL breakfast symposium »

Key Opinion Leader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$302.26

-45.18 (-13.00%)

, WMT

Walmart

$97.75

1.01 (1.04%)

16:14
01/18/19
01/18
16:14
01/18/19
16:14
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks opened higher and…

TSLA

Tesla

$302.26

-45.18 (-13.00%)

WMT

Walmart

$97.75

1.01 (1.04%)

CVS

CVS Health

$65.49

2.13 (3.36%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

FB

Facebook

$150.01

1.77 (1.19%)

AAPL

Apple

$156.85

0.99 (0.64%)

QCOM

Qualcomm

$55.26

0.44 (0.80%)

FND

Floor & Decor

$31.99

2.34 (7.89%)

OZK

Bank OZK

$32.07

4.47 (16.20%)

VFC

VF Corp.

$82.39

9.135 (12.47%)

NLS

Nautilus

$7.00

-4.76 (-40.48%)

CASA

Casa Systems

$11.23

-3.17 (-22.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

SNE

Sony

$50.08

0.58 (1.17%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Periodicals
Sony Music ends working relationship with R. Kelly, Variety reports »

Sony Music has opted to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$64.58

0.53 (0.83%)

16:12
01/18/19
01/18
16:12
01/18/19
16:12
Hot Stocks
Prologis, Ivanhoe Cambridge form $880M joint venture in Brazil »

Prologis and Ivanhoe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

CYDY

CytoDyn

$0.00

(0.00%)

16:10
01/18/19
01/18
16:10
01/18/19
16:10
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHF

WhiteHorse Finance

$13.58

-0.105 (-0.77%)

16:09
01/18/19
01/18
16:09
01/18/19
16:09
Hot Stocks
WhiteHorse Finance, STRS Ohio form JV to invest in debt facilities »

WhiteHorse Finance, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CB

Chubb

$133.43

0.6 (0.45%)

16:07
01/18/19
01/18
16:07
01/18/19
16:07
Hot Stocks
Chubb sees Q4 net catastrophe loss approximately $585M pre-tax, $505M after tax »

Chubb announced net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

ESEA

Euroseas

$0.80

-0.0332 (-3.98%)

16:07
01/18/19
01/18
16:07
01/18/19
16:07
Hot Stocks
Euroseas receives Nasdaq notice of non-compliance »

Euroseas Ltd. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$75.68

0.08 (0.11%)

, SSNLF

Samsung

$0.00

(0.00%)

16:04
01/18/19
01/18
16:04
01/18/19
16:04
Hot Stocks
FDA approves Samsung Bioepis-Merck biosimilar to Roche's Herceptrin »

The FDA announced that it…

MRK

Merck

$75.68

0.08 (0.11%)

SSNLF

Samsung

$0.00

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 28

    Jan

  • 01

    Feb

  • 16

    Feb

  • 18

    Mar

  • 11

    Apr

  • 18

    May

NKE

Nike

$80.35

1.23 (1.55%)

15:40
01/18/19
01/18
15:40
01/18/19
15:40
Options
Nike calls lead puts more than 4:1 as shares extend gains »

Nike calls lead puts more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.